Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03056833 · ClinicalTrials.gov registry record · Phase 1
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
A Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Ronald Buckanovich.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 8
- Study locations
NCT03056833 is a Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by Ronald Buckanovich. The registered enrollment target is 35 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The trial reports 8 study locations across 2 states.
The verdict
NCT03056833, a Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by Ronald Buckanovich.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 8
- Study locations
Study Summary
Investigators hypothesize that concurrent ribociclib treatment and chemotherapy will enhance the response to platinum-based therapy and maintenance therapy will slow ovarian cancer tumor growth leading to prolongation in progression free survival.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG ribociclib
Study Locations (8)
Pennsylvania
- UPMC Hillman Cancer Center Upper St. Clair - Bethel Park
- UPMC Hillman Cancer Center Arnold Palmer at Mountain View - Greensburg
- UPMC Hillman Cancer Center Arnold Palmer Medical at Norwin - Irwin
- UPMC Hillman Cancer Center Arnold Palmer at Mt Pleasant - Mount Pleasant
- University of Pittsburgh Medical Center - Pittsburgh
- UPMC Hillman Cancer Center Passavant (OHA) - Pittsburgh
- UPMC Hillman Cancer Center Washington - Washington
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-06-10 |
| Est. Completion | 2022-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03056833
The ClinicalTrials.gov registry entry for NCT03056833 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Ronald Buckanovich, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT03056833 reports 8 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Michigan.
Frequently Asked Questions
What is clinical trial NCT03056833 about?
NCT03056833 is a clinical study titled "Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer". Investigators hypothesize that concurrent ribociclib treatment and chemotherapy will enhance the response to platinum-based therapy and maintenance therapy will slow ovarian cancer tumor growth leading to prolongation in progression free survival.
What is the current status of trial NCT03056833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2017-06-10. Estimated completion is 2022-08-01.
What conditions does trial NCT03056833 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma.
What interventions are being tested in trial NCT03056833?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), ribociclib (DRUG).
Who is sponsoring clinical trial NCT03056833?
This trial is sponsored by Ronald Buckanovich, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03056833 being conducted?
This trial has 8 study locations across Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.